Histogenics Corporation Company Profile (NASDAQ:HSGX)

About Histogenics Corporation (NASDAQ:HSGX)

Histogenics Corporation logoHistogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HSGX
  • CUSIP: N/A
  • Web: www.histogenics.com
Capitalization:
  • Market Cap: $39.9 million
  • Outstanding Shares: 22,166,000
Average Prices:
  • 50 Day Moving Avg: $1.68
  • 200 Day Moving Avg: $1.70
  • 52 Week Range: $1.45 - $4.47
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.31 per share
  • Price / Book: 5.81
Profitability:
  • EBIDTA: ($27,500,000.00)
  • Return on Equity: -314.43%
  • Return on Assets: -91.66%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 6.34%
  • Quick Ratio: 6.34%
Misc:
  • Average Volume: 62,791 shs.
  • Beta: 1.38
  • Short Ratio: 2.45
 

Frequently Asked Questions for Histogenics Corporation (NASDAQ:HSGX)

What is Histogenics Corporation's stock symbol?

Histogenics Corporation trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics Corporation's earnings last quarter?

Histogenics Corporation (NASDAQ:HSGX) announced its earnings results on Thursday, May, 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.07. During the same period last year, the business earned ($0.60) earnings per share. View Histogenics Corporation's Earnings History.

Where is Histogenics Corporation's stock going? Where will Histogenics Corporation's stock price be in 2017?

5 analysts have issued 1 year target prices for Histogenics Corporation's shares. Their forecasts range from $3.50 to $11.00. On average, they expect Histogenics Corporation's share price to reach $5.88 in the next twelve months. View Analyst Ratings for Histogenics Corporation.

What are analysts saying about Histogenics Corporation stock?

Here are some recent quotes from research analysts about Histogenics Corporation stock:

  • 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (5/16/2017)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following the Q1/17 results. Histogenics reported zero revenues and a diluted net loss of $5.8M, compared to CG/consensus of $7.5M/$6.9M net loss, and LPS of $(0.27), in line with CG/consensus estimate of $(0.27). Histogenics provided numerous clinical trial metrics to demonstrate to investors the improved momentum of enrollment in the NeoCart Phase 3 trial. Specifically, trial enrollment, as of the Q1/17 call, stands at 230 patients out of 245 total, and up from 214 as of the Q4/16 call, and just 15 shy of complete trial enrollment. Management reiterated its expectation to complete enrollment by Q2/17 and already has 15 additional patients who have consented to the trial with more patients in the pipeline if needed. Management indicated they would announce completed enrollment in early July 2017." (5/11/2017)

Are investors shorting Histogenics Corporation?

Histogenics Corporation saw a increase in short interest in May. As of May 15th, there was short interest totalling 95,242 shares, an increase of 19.4% from the April 28th total of 79,740 shares. Based on an average trading volume of 80,387 shares, the days-to-cover ratio is presently 1.2 days.

Who are some of Histogenics Corporation's key competitors?

Who are Histogenics Corporation's key executives?

Histogenics Corporation's management team includes the folowing people:

  • Garheng Kong M.D. Ph.D., Independent Chairman of the Board
  • Adam Gridley, President, Chief Executive Officer, Director
  • Jonathan I. Lieber, Chief Financial Officer
  • Stephen Richard Kennedy, Chief Technology Officer
  • Gloria Matthews Ph.D., Chief Medical Officer
  • Joshua J. Baltzell, Independent Director
  • David N. Gill, Independent Director
  • John H. Johnson, Independent Director
  • Michael Lewis, Independent Director
  • Kevin L. Rakin, Independent Director

When did Histogenics Corporation IPO?

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who owns Histogenics Corporation stock?

Histogenics Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Third Security LLC (13.03%), Sofinnova Management VIII L.L.C. (10.06%), Perceptive Advisors LLC (8.61%), FMR LLC (8.38%), Sabby Management LLC (5.31%) and Palo Alto Investors LLC (1.47%). Company insiders that own Histogenics Corporation stock include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Institutional Ownership Trends for Histogenics Corporation.

Who sold Histogenics Corporation stock? Who is selling Histogenics Corporation stock?

Histogenics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Histogenics Corporation.

Who bought Histogenics Corporation stock? Who is buying Histogenics Corporation stock?

Histogenics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sabby Management LLC and Carl Domino Inc. Company insiders that have bought Histogenics Corporation stock in the last two years include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Insider Buying and Selling for Histogenics Corporation.

How do I buy Histogenics Corporation stock?

Shares of Histogenics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics Corporation's stock price today?

One share of Histogenics Corporation stock can currently be purchased for approximately $1.80.


MarketBeat Community Rating for Histogenics Corporation (NASDAQ HSGX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Histogenics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Histogenics Corporation (NASDAQ:HSGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $5.88 (226.39% upside)

Analysts' Ratings History for Histogenics Corporation (NASDAQ:HSGX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
5/11/2017Canaccord GenuityReiterated RatingBuyMediumView Rating Details
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 -> $11.00N/AView Rating Details
9/7/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
8/11/2016BTIG ResearchUpgradeNeutral -> Buy$3.50N/AView Rating Details
11/13/2015Cowen and CompanyLower Price TargetOutperform$17.00 -> $12.50N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Histogenics Corporation (NASDAQ:HSGX)
Earnings by Quarter for Histogenics Corporation (NASDAQ:HSGX)
Earnings History by Quarter for Histogenics Corporation (NASDAQ HSGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.34)($0.27)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.47)($1.60)ViewN/AView Earnings Details
11/10/2016Q316($0.62)($0.70)ViewListenView Earnings Details
8/11/2016Q216($0.60)($0.61)ViewListenView Earnings Details
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details
2/26/2015Q414$0.66$0.54ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Histogenics Corporation (NASDAQ:HSGX)
Current Year EPS Consensus Estimate: $-1.33 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Histogenics Corporation (NASDAQ:HSGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Histogenics Corporation (NASDAQ:HSGX)
Insider Ownership Percentage: 23.80%
Institutional Ownership Percentage: 50.12%
Insider Trades by Quarter for Histogenics Corporation (NASDAQ:HSGX)
Institutional Ownership by Quarter for Histogenics Corporation (NASDAQ:HSGX)
Insider Trades by Quarter for Histogenics Corporation (NASDAQ:HSGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017David N GillDirectorBuy3,000$1.68$5,040.00View SEC Filing  
12/15/2016David N GillDirectorBuy3,000$1.65$4,950.00View SEC Filing  
12/9/2016David N GillDirectorBuy5,000$1.92$9,600.00View SEC Filing  
12/2/2016Jonathan I LieberCFOBuy5,000$1.95$9,750.00View SEC Filing  
12/1/2016Adam GridleyInsiderBuy5,000$2.01$10,050.00View SEC Filing  
9/29/2016Split Rock Partners Ii, LpMajor ShareholderBuy276,801$2.25$622,802.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Histogenics Corporation (NASDAQ:HSGX)
Latest Headlines for Histogenics Corporation (NASDAQ:HSGX)
Source:
DateHeadline
finance.yahoo.com logoHistogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
finance.yahoo.com - June 27 at 5:56 PM
americanbankingnews.com logoHistogenics Corporation (HSGX) Upgraded at ValuEngine
www.americanbankingnews.com - June 24 at 12:38 AM
finance.yahoo.com logoFresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
finance.yahoo.com - June 21 at 3:21 PM
americanbankingnews.com logoHistogenics Corporation (HSGX) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - June 21 at 7:34 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 7 at 12:45 AM
finance.yahoo.com logoHistogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer
finance.yahoo.com - June 5 at 10:29 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Sees Large Growth in Short Interest
www.americanbankingnews.com - June 4 at 7:08 AM
americanbankingnews.com logo Analysts Expect Histogenics Corp (HSGX) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM
finance.yahoo.com logoEdited Transcript of HSGX earnings conference call or presentation 11-May-17 12:30pm GMT
finance.yahoo.com - May 19 at 10:17 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 16 at 11:58 PM
finance.yahoo.com logoHistogenics Corporation to Present at Upcoming Industry Conferences
finance.yahoo.com - May 16 at 11:17 AM
finance.yahoo.com logoHistogenics Corporation Receives Innovation Award
finance.yahoo.com - May 15 at 11:03 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 12:46 AM
seekingalpha.com logoHistogenics' (HSGX) CEO Adam Gridley on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 6:21 PM
finance.yahoo.com logoHistogenics Corporation Announces First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 11 at 6:21 PM
finance.yahoo.com logoHistogenics reports 1Q loss
finance.yahoo.com - May 11 at 6:21 PM
finance.yahoo.com logoInvestor Network: Histogenics Corp. to Host Earnings Call
finance.yahoo.com - May 11 at 6:21 PM
americanbankingnews.com logoCanaccord Genuity Reiterates Buy Rating for Histogenics Corp (HSGX)
www.americanbankingnews.com - May 11 at 5:24 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Issues Earnings Results
www.americanbankingnews.com - May 11 at 1:52 PM
streetinsider.com logoHistogenics (HSGX) Announces Agreement With Japan PMDA on Regulatory Pathway for NeoCart
www.streetinsider.com - May 8 at 5:26 PM
finance.yahoo.com logoHistogenics Announces Agreement With the Japan Pharmaceuticals and Medical Devices Agency Regarding Japanese Regulatory Pathway for NeoCart®
finance.yahoo.com - May 8 at 5:26 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Given News Sentiment Score of 0.09
www.americanbankingnews.com - May 3 at 10:32 AM
americanbankingnews.com logo Brokerages Expect Histogenics Corp (HSGX) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - May 2 at 8:02 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Receiving Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 27 at 6:56 PM
finance.yahoo.com logoHistogenics Corporation To Announce First Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - April 27 at 6:20 PM
finance.yahoo.com logoHistogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
finance.yahoo.com - April 24 at 5:27 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Getting Somewhat Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 23 at 6:36 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Getting Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 20 at 3:47 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 12:53 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Earning Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 15 at 11:45 AM
americanbankingnews.com logoZacks: Brokerages Expect Histogenics Corp (HSGX) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - April 11 at 2:12 PM
seekingalpha.com logoHistogenics Corporation (HSGX) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 10:18 AM
finance.yahoo.com logoHistogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference
finance.yahoo.com - March 29 at 10:44 AM
biz.yahoo.com logoHISTOGENICS CORP Files SEC form 8-K, Other Events
biz.yahoo.com - March 27 at 5:22 PM
americanbankingnews.com logoHC Wainwright Analysts Give Histogenics Corp (HSGX) a $4.00 Price Target
www.americanbankingnews.com - March 24 at 7:50 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 23 at 12:16 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 21 at 3:40 PM
finance.yahoo.com logoEdited Transcript of HSGX earnings conference call or presentation 16-Mar-17 12:30pm GMT
finance.yahoo.com - March 17 at 6:00 PM
benzinga.com logoHistogenics Corporation Announces Financial and...
www.benzinga.com - March 16 at 4:24 PM
seekingalpha.com logoHistogenics' (HSGX) CEO Adam Gridley on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 4:24 PM
us.rd.yahoo.com logoHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
us.rd.yahoo.com - March 16 at 4:24 PM
biz.yahoo.com logoQ4 2016 Histogenics Corp Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 4:24 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoHistogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
us.rd.yahoo.com - March 9 at 3:50 PM
us.rd.yahoo.com logo8:36 am Histogenics announces the publication in the Journal of Orthopaedic Research of a peer-reviewed publication entitled Mechanical Properties and Structure-Function Relationships of Human Chondrocyte-Seeded Cartilage Constructs After I
us.rd.yahoo.com - March 9 at 3:50 PM
finance.yahoo.com logoHistogenics Corporation to Announce 2016 Financial Results on March 16, 2017
finance.yahoo.com - March 2 at 6:07 PM
finance.yahoo.com logoHistogenics Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - February 23 at 5:46 PM
finance.yahoo.com logoZimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?
finance.yahoo.com - February 8 at 11:25 PM
finance.yahoo.com logoWill Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
finance.yahoo.com - February 8 at 11:25 PM
finance.yahoo.com logoQuest Diagnostics (DGX) Q4 Earnings: What Lies in Store?
finance.yahoo.com - January 16 at 9:01 AM

Social

Chart

Histogenics Corporation (HSGX) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff